Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study
, Elisa Tribocco 1, Chiara Rosso 1,*, Angelo Armandi 1, Marta Vernero 2, Elisabetta Bugianesi 1, Marco Astegiano 3, Giorgio Maria Saracco 1 and Gian Paolo Caviglia 1Round 1
Reviewer 1 Report
This is a useful study
Author Response
Dear Reviewer, thank you very much for appreciating our study. We think that it is a contribute to every day clinical practice.
Reviewer 2 Report
The study entitled “Switching from biosimilar to biosimilar adalimumab, including multiple switching, in Crohn's disease: a prospective study” presents data from clinical observation of patients with Crohn’s disease who switched from the biosimilar of adalimumab ABP 501 to SB5. The patients were observed for six months, and the authors recorded no side effects of mediational switch from the originator to SB5. Of note, the authors stress that medication switch should not be made if CRP protein is above 5 mg/L as it reduce the chance of successful drug switch. I would only recommend the authors to add SD values to Figure 1.
Author Response
Dear Reviewer, thank you very much for appreciating our study.
Regarding Figure 1, since CRP values at T0 were dichotomized as negative or positive, the SD cannot be calculated: we added the p value of the Chi squared test to provide the statistical significance of the comparison.
